期刊文献+

IRF4 and IRF8: governing the virtues of B lymphocytes 被引量:1

IRF4 and IRF8: governing the virtues of B lymphocytes
原文传递
导出
摘要 Interferon regulatory factor 4 (IRF4) and IRF8 are critical regulators of immune system development and function. In B lymphocytes, IRF4 and IRF8 have been shown to control important events during their development and maturation including pre-B cell differentiation, induction of B cell tolerance pathways, marginal zone B cell development, germinal center reaction and plasma cell differentiation. Mechanistically, IRF4 and IRF8 are found to function redundantly to control certain stages of B cell development, but in other stages, they function nonredundantly to play distinct roles in B cell biology. In line with their essential roles in B cell development, deregulated expressions of IRF4 and IRF8 have been associated to the pathogenesis of several B cell malignancies and diseases. Recent studies have elucidated diverse transcriptional networks regulated by IRF4 and IRF8 at distinct B cell developmental stages and related malignancies. In this review we will discuss the recent advances for the roles of IRF4 and IRF8 during B cell development and associated diseases. Interferon regulatory factor 4 (IRF4) and IRF8 are critical regulators of immune system development and function. In B lymphocytes, IRF4 and IRF8 have been shown to control important events during their development and maturation including pre-B cell differentiation, induction of B cell tolerance pathways, marginal zone B cell development, germinal center reaction and plasma cell differentiation. Mechanistically, IRF4 and IRF8 are found to function redundantly to control certain stages of B cell development, but in other stages, they function nonredundantly to play distinct roles in B cell biology. In line with their essential roles in B cell development, deregulated expressions of IRF4 and IRF8 have been associated to the pathogenesis of several B cell malignancies and diseases. Recent studies have elucidated diverse transcriptional networks regulated by IRF4 and IRF8 at distinct B cell developmental stages and related malignancies. In this review we will discuss the recent advances for the roles of IRF4 and IRF8 during B cell development and associated diseases.
机构地区 Department of Genetics
出处 《Frontiers in Biology》 CAS CSCD 2014年第4期269-282,共14页 生物学前沿(英文版)
关键词 IRF4 IRF8 B lymphocytes transcriptional regulation leukemia and lymphoma B cell development IRF4, IRF8, B lymphocytes, transcriptional regulation, leukemia and lymphoma, B cell development
  • 相关文献

参考文献113

  • 1Acquaviva J, Chen X, Ren R (2008). IRF-4 functions as a tumor suppressor in early B-cell development. Blood, 112(9): 3798–3806.
  • 2Affer M, Chesi M, Chen W D, Keats J J, Demchenko Y N, Tamizhmani K, Garbitt V M, Riggs D L, Brents L A, Roschke A V, Van Wier S, Fonseca R, Bergsagel P L, Kuehl W M (2014). Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia, (epub ahead of print).
  • 3Aldinucci D, Celegato M, Borghese C, Colombatti A, Carbone A (2011). IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion. Br J Haematol, 152(2): 182–190.
  • 4Aldinucci D, Rapana’ B, Olivo K, Lorenzon D, Gloghini A, Colombatti A, Carbone A (2010). IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. Br J Haematol, 148(1): 115–118.
  • 5Alizadeh A A, Eisen M B, Davis R E, Ma C, Lossos I S, Rosenwald A, Boldrick J C, Sabet H, Tran T, Yu X, Powell J I, Yang L, Marti G E, Moore T, Hudson J Jr, Lu L, Lewis D B, Tibshirani R, Sherlock G, Chan W C, Greiner T C, Weisenburger D D, Armitage J O, Warnke R, Levy R, Wilson W, Grever MR, Byrd J C, Botstein D, Brown P O, Staudt L M (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403(6769): 503–511.
  • 6Allan J M, Sunter N J, Bailey J R, Pettitt A R, Harris R J, Pepper C, Fegan C, Hall A G, Deignan L, Bacon C M, Pointon J C, Houlston R S, Broderick P, Mainou-Fowler T, Jackson G H, Summerfield G, Evans P A, Strefford J C, Parker A, Oscier D, Pratt G, Allsup D J (2010). Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. Leukemia, 24(4): 877–881.
  • 7Arguello M, Sgarbanti M, Hernandez E, Mamane Y, Sharma S, Servant M, Lin R, Hiscott J (2003). Disruption of the B-cell specific transcriptional program in HHV-8 associated primary effusion lymphoma cell lines. Oncogene, 22(7): 964–973.
  • 8Banerjee S, Lu J, Cai Q, Saha A, Jha H C, Dzeng R K, Robertson E S (2013). The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog, 9(5): e1003314.
  • 9Becker A M, Michael D G, Satpathy A T, Sciammas R, Singh H, Bhattacharya D (2012). IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. Blood, 119(9): 2003–2012.
  • 10Bevington S, Boyes J (2013). Transcription-coupled eviction of histones H2A/H2B governs V(D)J recombination. EMBO J, 32(10): 1381–1392.

同被引文献1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部